Anticholinergic medications in patients admitted with cognitive impairment or falls (AMiCI). The impact of hospital admission on anticholinergic cognitive medication burden. Results of a multicentre observational study. by Weichert, I et al.
For Peer Review
 
 
 
 
 
 
Anticholinergic medications in patients admitted with 
cognitive impairment or falls (AMiCI). The impact of 
hospital admission on anticholinergic medication burden. 
Results of a multicentre observational study. 
 
 
Journal: Journal of Clinical Pharmacy and Therapeutics 
Manuscript ID JCPT-2017-4488.R3 
Manuscript Type: Original Article 
Date Submitted by the Author: 05-Feb-2018 
Complete List of Authors: Weichert, Immo; The Ipswich Hospital, Acute Medicine Department 
Romero-Ortuno, Roman; Cambridge University Hospitals NHS 
Trust,  Addenbrooke's Hospital, Department of Medicine for the Elderly; 
University of Cambridge Clinical Gerontology, Department of Public Health 
and Primary Care 
Tolonen, Jukka; Helsinki University Hospitals, Department of Medicine and 
Rehabilitation 
Soe-Wright, Thander ; The Ipswich Hospital, Acute Medicine Department 
Lebus, Caroline; Cambridge University Hospitals NHS Trust, Addenbrooke's 
Hospital, Department of Acute Medicine 
Choudhury, Sarah; East and North Hertfordshire NHS Trust, Lister Hospital, 
Department of Acute Medicine 
Nadarajah, Channa; East and North Hertfordshire NHS Trust, Lister 
Hospital, Department of Acute Medicine 
Nanayakkara, Prabath; VU University Medical Center, Department of Acute 
Medicine 
Orrù, Michela; Universita degli Studi di Roma La Sapienza Dipartimento di 
Medicina Clinica, Department of Medical-Surgical Sciences and 
Translational Medicine 
Di Somma, Salvatore; Universita degli Studi di Roma La Sapienza 
Dipartimento di Medicina Clinica, Department of Medical-Surgical Sciences 
and Translational Medicine 
Keywords: 
Anticholinergics, Anticholinergic cognitive burden, Cholinesterase inhibitors, 
Cognitive impairment, Falls, Medication review, Medicines Optimisation 
  
 
 
Journal of Clinical Pharmacy and Therapeutics
For Peer Review
WHAT IS KNOWN 
 
The increasing age of the population is a success of individual and public health that 
unfortunately goes hand in hand with multimorbidity and polypharmacy. Of specific concern 
are prescription and over the counter medications that have anticholinergic activity. These 
include a wide variety of drugs including those for hypertension, cardiovascular, and 
pulmonary disease. Over the last 25 years there has been increasing evidence that cholinergic 
blockade in the central nervous system has been linked to adverse effects such as confusion, 
behavioural disturbances, reduced executive and motor functions, altered emotions 
1–5
 and 
increased risk of falls, delirium, chronic cognitive impairment, and mortality. 
6–9
 An age-
related increase in permeability of the blood-brain barrier is thought to contribute to this 
problem. 
10
 The use of multiple drugs with drugs with anticholinergic properties (DAPs) is 
thought to have an additive effect. The cumulative anticholinergic cognitive burden (ACB) of 
all therapies predicts more accurately the risk of adverse events.
11
 Acetylcholinesterase 
inhibitors (AChE-I) are used in the treatment of mild to moderate Alzheimer’s disease. 12 Up 
to 60% of patients with dementia are reported to receive at least one anticholinergic drug. 
13,14
 
The combination of both pro- and anticholinergics can elicit an antagonistic response and 
further hasten cognitive decline. 
15
 
Review and optimisation of medication are recommended by specialist representative bodies. 
16
 The widely used STOPP/START criteria for potentially inappropriate prescribing in older 
people were expanded in the latest version of 2014 to cover more drugs that have 
anticholinergic activity. 
17
 The 2015 revision of the Beer’s criteria by the American Geriatric 
Society recommends avoiding anticholinergics in patients with chronic cognitive impairment 
and delirium. 
18
 The Silver Book by the British Geriatric Society defines standards for urgent 
and emergency care of frail older patients and advocates a medicines review at the time of 
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crisis, with particular regard to sedative, psychotropic, hypotensive or anticholinergic 
medications. 
19
 
 
OBJECTIVE 
 
Little is known about how effective the recommended review of DAPs is in patients at risk 
who present acutely and how often drugs with anticholinergic properties are used temporarily 
during an admission. We investigated the impact of hospital admission on the anticholinergic 
burden and the use of relevant medications in medical patients admitted with a diagnosis of 
delirium, chronic cognitive impairment, or falls. As such, our main objective was to 
investigate the possible change of the ACB from admission to discharge and the temporary 
use of DAPs. The secondary goal was to identify differences in diagnostic and demographic 
subgroups including death and readmission. 
 
METHODS  
 
This multi-centre observational study, which took place between October 2014 and March 
2016 was conducted in seven acute hospitals in the UK, Finland, The Netherlands and Italy 
as a collaboration through the Global Research on Acute Conditions Team (GREAT 
Network, www.greatnetwork.org). None of the centres involved changed their approach to 
medication review or optimisation in preparation for this study but continued throughout with 
their usual clinical current practise. 
The project was screened in accordance with the recommendations of the UK Healthcare 
Quality Improvement Partnership and the NHS Health Research Authority and categorised as 
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a service evaluation. 
20,21
 All centres registered the project with their local audit departments 
or obtained approval by their relevant institutional review boards.   
Each centre selected patients prospectively over a period of at least one month. We included 
unscheduled emergency admissions under the medical teams (i.e. acute medicine, general 
internal medicine, and geriatric medicine) with a diagnosis of chronic cognitive impairment 
or dementia, acute confusional state or delirium, or falls. We recorded demographics, date of 
admission, diagnoses that led to inclusion in the study, use of AChE-Is, whether a new 
diagnosis of dementia had been made by discharge, the date of discharge or death, and if 
patients were readmitted or died within 30 days after discharge. To record DAPs we adapted 
the 2012 revision of the original ACB scale. 
22
 Medication names were translated to those in 
use in the participating centres and were grouped by indication and ACB. We added the 
opioid Tramadol due to its central type-3 muscarinic receptor antagonism. 
23
 The relevant 
medications, as well as each patient's cumulative burden on admission and discharge and if 
used during the hospital stay, were recorded (Figure 1).  
We compared demographic subgroups, diagnoses, length of stay (day 0 discharge, short stay 
of up to 3 days, stay up to 1 week and stay longer than one week), outcomes including 
readmission and discharge to their own home. The Shapiro-Wilk test was used to test for 
normality, the Wilcoxon signed-rank test to compare the anticholinergic burden scores on 
admission and discharge, the two sample t-test, Yates and Pearson’s chi-square test to analyse 
subgroups. Multivariate binary logistic regression was conducted to identify possible baseline 
clinical, demographic and geographical confounders, including patients on and those not on 
DAPs, predicting an increase vs. decrease in ACB at discharge, as well as readmission and 
mortality. The point of statistical significance was set at p < 0.05. Statistical analysis was 
performed with RStudio version 1.0.143, apart from the multivariate binary logistic 
regression models, where IBM SPSS version 22.0 was used. 
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RESULTS AND DISCUSSION 
 
The baseline characteristics of the 549 patients included are summarized in table 1. 60.8% of 
the patients were taking DAPs on admission. Mean ACB score was 2.1 (range 1-10, SD 1.5). 
19.1% of all patients had an ACB of 3 or more (mean = 4, range 3-10, SD 1.3).There was no 
difference between ACB scores on admission compared to discharge or death (p=0.569). 
There was no change in ACB scores in 59.2% of patients. 21.1% of had their ACB score 
reduced by a mean of 1.7 (range 1-6, SD 1.1). 19.7% of patients had their ACB increased by 
a mean of 1.6 (range 1-5, SD 1.0).  22.8% of DAP naïve patients were discharged on DAPs. 
No predictors of a decrease in the ACB scores were identified (Table 2a). Patients from the 
UK or Finland were less likely to have their ACB score increased. A higher number of DAPs 
used temporarily during admission was associated with a higher risk of ACB score increase 
on discharge (OR=1.82, 95% CI for OR: 1.36-2.45, p<0.001 -Table 2b).  
Of 98 medications on the ACB scale, 56 were observed in our patients. Figure 2 shows each 
drug on admission and discharge. The lighter shaded bars show the percentage of patients 
who had each drug discontinued or newly commenced by discharge.  In Figure 3 the same 
medications are weighted by their anticholinergic burden to represent the percentage of each 
medication on the cumulative burden. 17 medications with the highest individual ACB of 3 
were recorded on admission. These represent 13.8% of all recorded drugs used or 31.9% of 
the anticholinergic burden. 6.0% of all patients were taking at least one of them. The 
anticholinergic load in our patients was predominantly caused by medications with a low 
individual burden which were accounting for 64.9% of the total burden (table 3).  
 
DAPs were used temporarily during the admission in 21.9% of all patients. Their mean ACB 
score was low at 0.4 (range 0-6, SD 0.9). We found 26 different medications, most frequently 
Morphine, Codeine, Haloperidol, Diazepam and Furosemide. 
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Tramadol, which we had added in our adaption of the ACB scale, was only seen in 2.7% of 
patients on admission and was used temporarily in 2.9%. 
 
The results of our subgroup analysis are shown in tables 5 a – d. 
 
Shot stay patients (stay for a maximum of three days) were the only group that saw their 
ACB reduced (p= 0.018, table 5d). This group had fewer patients on DAPs on discharge 
(48.4% vs 60.5%, p= 0.022), saw equal numbers of patients who had their anticholinergics 
reduced but fewer patients who had theirs increased (8.9% vs 22.8%, p= 0.001) compared to 
the patients who were not short stay. 
Patients who could not return home but were discharged to sheltered accommodation, 
residential or nursing home, were older than the rest of the patients (82.0 vs 76.5 years, p< 
0.001) but did not differ in ACB scores. They were the only subgroup which saw a significant 
increase in ACB by discharge (p = 0.016 – table 5d). More than double of these patients had 
their ACB increased (15.4 vs. 32.7%, p < 0.001) and they also saw a much higher temporary 
use of DAPs (in 34.6% vs 16.4% of patients, p< 0.001) with a higher burden of 
anticholinergics used temporarily (mean 0.73, SD 1.24 vs mean 0.22, SD 0.55, p< 0.001) 
compared to those who went back home.  
Men in our study were younger than women (mean 77.7 vs. 81.0 years, p=0.003) and were 
more likely to be prescribed temporary anticholinergic drugs (26.6% vs. 18.1%, p=0.022, 
table 5a ) with a higher burden of anticholinergics used temporarily (mean 0.50, SD 1.1 vs 
mean 0.3, SD 0.7 p= 0.004).  
Patients who died during index admission as well as those who were readmitted or died 
within the 30 day follow up period did not differ from the rest of the patients in ACB on 
admission or discharge/death (table 5 d). Those who died had a smaller proportion of patients 
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on DAPs at death. Our data do not allow us to differentiate between expected and unexpected 
deaths; though it is likely that this reduction in number of patients may be due to the 
deliberate stopping of medications in those who were not able to take them anymore or who 
had been commenced on an end of life care pathway. 
Prescribing behaviour in all diagnostic subgroups of dementia, delirium or falls, as well as in 
those with newly diagnosed dementia, was similar with no statistically significant change in 
ACB scores or number of patients on anticholinergic drugs, as well as with regards to the 
temporary use of drugs with anticholinergic properties (table 5 b).  Figure 4 shows the 
distributions of anticholinergic burden in each of the diagnostic groups on admission and 
discharge.  
 
AChE-I (table 5b) were found on admission in 18.2% of patients with a diagnosis of chronic 
cognitive impairment (or in 6.7% of all patients). Of these patients on procholinergics, 54.1% 
were also taking DAPs. This subgroup did not differ from the rest with regards to the number 
of patients on DAPs, ACB scores, or the number of naïve patients newly started on DAPs 
(table 5c). Table 6 lists DAPs found on admission in patients on AChE-Is. Temporary DAPs 
were prescribed less in this group compared to patients not on procholinergics on admission 
(13.5% vs 22.5% of patients, p, 0.001). This combination of antagonistic drugs makes little 
sense but is unfortunately frequently encountered. 
14,24
  Some of the side effects of dementia 
drugs, such as urinary frequency, incontinence, diarrhoea, or insomnia may be misinterpreted 
as new comorbidities or manifestations of frailty in patients with cognitive impairment. 
25
 
The resulting prescribing of anticholinergics will offset their efficiency and may hasten 
cognitive decline. 
 
The use of drugs with the highest anticholinergic burden was low amongst our patients and 
the anticholinergic load was caused predominantly by drugs with lesser activity. Adverse 
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drug events are the result of the anticholinergic load of multiple medications rather than of a 
single drug. 
26
 Combined anticholinergic use increases hospitalizations and mortality in older 
people 
27
 and hastens cognitive decline. For one point in the ACB, a decline in the Mini-
mental State Examination 
28
  (MMSE) score of 0.33 over 2 years has been suggested. 
7
 
Furthermore, an increase in the cumulative ACB by one has been linked with a 26% increase 
in mortality. 
29
   
 
More than one-third of medications included in the ACB scale were not in use in our patients. 
This reflects the availability of these medications within the countries that took part in our 
study. In a globalised world with access to non-formulary drugs when travelling abroad or by 
purchasing them online via regulated or rogue pharmacies, we do not suggest the use of a 
shortened ACB scale. 
 
Temporary medications were used in more than 1 in 5 patients. This was the same in all 
diagnostic subgroups including patients with an acute delirium, potentially worsening their 
confusion. It may be difficult to fully avoid these but non-pharmacological approaches to 
prevent or treat delirium including addressing the environment in which patients are cared for 
may reduce their need. 
30
  
 
Our study is not without limitations. Our aim was to analyse the impact of an acute admission 
on the anticholinergic burden. We did not record comorbidities and did not identify 
terminally ill patients or those with end-stage dementia. Overall, rates for readmission and 
mortality were nevertheless similar to those in patients described in large cohort studies 
looking at outcomes of elderly patients admitted. 
31
 All participating centres were acute 
hospitals either at regional or teaching hospital level. We did not look into potential 
differences of the organisation of medication management in these facilities. The clinicians 
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involved in the project were also – at least in part – the same clinicians looking after the 
patients included in our study. These factors may have potentially also accounted for the 
regional differences highlighted by the regression analysis i.e. that for patients recruited in 
UK or Finnish centres the probability for an increase in ACB score was lower. Studies 
comparing the organisation of medicines review and optimisation in different health care 
systems will be necessary to investigate this in future. 
 
Our results mirror community-based studies that have shown that there is considerable scope 
for improvement of prescribing practices in older people. 
14
 Theoretical models have shown 
that a reduction in anticholinergic burden can be achieved in 59% of patients that score at 
least one point on the ACB scale and that a reduction from a score of 3 or above to 2 is 
possible in 85% of the cases. 
32
 Various approaches to tackle anticholinergic burden have 
been suggested. For many indications of DAPs there exist alternatives that allow reducing the 
anticholinergic load. This can include drugs with lesser or no anticholinergic activity or non-
pharmacological approaches. 
33
 The provision of guidelines and education alone do not seem 
to be sufficient ensure best medicines review and optimisation in older people. Random 
control trials have shown an improvement in the quality of prescribing and deprescribing via 
the use of multidisciplinary teams, geriatric case conferences, medication review by 
pharmacists and the use of information technology to support medication decisions. 
34
  
  
WHAT IS NEW AND CONCLUSION 
 
To our knowledge, this is the first multicentre study to investigate the effect of an acute 
admission on the anticholinergic cognitive burden. There was no reduction in cumulative 
scores in our patients who presented as unscheduled emergency admissions with a history of 
falls, acute delirium or dementia.  Similar numbers of patients had their ACB reduced or 
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increased. The same medications, whilst stopped in some patients, were started in others. 
More than one in five patients who were not taking anticholinergics when admitted were 
prescribed them by discharge. This prescribing pattern was the same for all diagnostic 
subgroups. Short stay patients had their ACB burden reduced by discharge. In contrast, 
patients who were not able to be discharged back to their home were the only subgroup 
identified which saw a significant increase in ACB from admission to discharge. Despite 
more than 25 years of evidence and national as well as international recommendations, much 
more needs to be done to improve medication management in these patients. “Imperative 
drugging – the ordering of medicine in any and every malady is no longer regarded as the 
chief function of the doctor” but “one of the first duties of the physician is to educate the 
masses not to take medicines.” 35,36 These quotes by Sir William Osler are even more valid 
today, nearly a century after his death. To substantiate them will require a joint effort from 
both primary and secondary care, through more education, more focused involvement from 
pharmacists and multidisciplinary teams, both in the community and in hospitals, and also by 
raising awareness in patients, their caregivers and support groups alike.  
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Table 1: Patient characteristics 
 
 
Number of Patients 549 
  
Female (%) 58.3 
Male (%) 41.7 
  
Mean Age (years) 79.6 
 
Patients aged 65 years or older 
 
89.8% 
 
Admission Diagnosis: 
 
 
Dementia (%) 27.0 
Acute delirium (%) 34.8 
Falls (%) 60.3 
Dementia diagnosed during admission (%) 4.9 
  
Patients on anticholinergics (%) 60.8 
Patients on cholinesterase inhibitors (%) 6.7 
  
Mean length of stay (days) 9.3 
  
30-day readmission rate as % of all patients 15.7 
as % of all patients that were discharged/survived 16.9 
  
Mortality during index admission in %  7.7 
Mortality within 30 days post discharge in % 4.0 
 
The datasets were complete for all but five patients (0.9 %) where follow-up information was 
unavailable. 
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Table 2: Multivariate binary logistic regression analysis 
a) Increase in ACB score 
 
 Odds 
Ratio 
95% C.I.* for 
Odds Ratio 
 Lower      Upper                                 
P value 
Age 1.01 0.99 1.04 0.224 
Sex 0.94 0.55 1.59 0.810 
UK centre 0.05 0.01 0.36 0.003 
Finnish centre 0.04 0.01 0.27 0.001 
Dutch centre 0.14 0.02 1.11 0.063 
Italian centre 0.47 0.06 3.86 0.481 
From care home 0.97 0.47 1.98 0.924 
Chronic cognitive 
impairment or dementia 
0.63 0.28 1.45 0.281 
Acute delirium or 
confusional state 
0.98 0.44 2.20 0.962 
Falls 1.08 0.47 2.52 0.852 
Temporary used DAPs 1.82 1.36 2.45 <0.001 
 
*Confidence interval 
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b) Decrease in ACB Score 
 
 Odds 
Ratio 
95% C.I. for Odds 
Ratio 
 Lower      Upper                                 
P value 
Age 0.99 0.97 1.01 0.372 
Sex 1.01 0.62 1.63 0.977 
UK centre 1.30 0.27 6.37 0.746 
Finnish centre 0.35 0.07 1.71 0.196 
Dutch centre 0.78 0.12 5.02 0.796 
Italian centre 0.66 0.10 4.22 0.663 
From care home 1.26 0.67 2.38 0.477 
Chronic cognitive 
impairment or dementia 0.82 0.39 1.69 0.583 
Acute delirium or 
confusional state 0.61 0.29 1.25 0.175 
Falls 0.52 0.19 1.00 0.053 
Temporary used DAPs 1.13 0.83 1.52 0.437 
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c) Inpatient mortality 
 
 Odds 
Ratio 
95% C.I. for Odds 
Ratio 
 Lower      Upper                                 
P value 
Age 1.06 1.02 1.12 0.010 
Sex 1.15 0.52 2.53 0.736 
UK centre 0.57 0.19 1.74 0.322 
Finnish centre 0.04 0.01 0.26 0.001 
Dutch centre 0.45 0.07 2.74 0.387 
Italian centre 0.89 0.12 3.34 0.435 
From care home 2.54 1.10 5.86 0.029 
Chronic cognitive 
impairment or dementia 
0.66 0.25 1.76 0.408 
Acute delirium or 
confusional state 
1.48 0.56 3.93 0.430 
Falls 0.45 0.16 1.28 0.135 
Temporary used DAPs 2.20 1.45 3.35 <0.001 
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2d) Readmission 
 Odds 
Ratio 
95% C.I. for Odds 
Ratio 
 Lower      Upper                                 
P value 
Age 1.01 0.99 1.03 0.316 
Sex 0.72 0.43 1.22 0.221 
UK centre 0.22 0.04 1.39 0.107 
Finnish centre 0.10 0.02 0.62 0.013 
Dutch centre 0.20 0.03 1.55 0.122 
Italian centre 0.45 0.05 3.79 0.460 
From care home 1.21 0.59 2.46 0.599 
Chronic cognitive 
impairment or dementia 
0.44 0.18 1.05 0.063 
Acute delirium or 
confusional state 
0.67 0.29 1.55 0.352 
Falls 0.64 0.27 1.51 0.306 
Temporary used DAPs 1.30 0.96 1.78 0.095 
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Table 3: Proportion of anticholinergic medications used in all patients on admission 
 
 ACB = 1 ACB = 2 ACB = 3 
% of DAPs  84.12  2.09 13.79 
% of total ACB 64.87  3.23 31.90 
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Table 4: Temporarily used medications with anticholinergic properties 
Medication % 
  
Morphine 28.3 
Codeine 19.2 
Haloperidol 15.0 
Diazepam 14.2 
Furosemide 14.2 
Tramadol 13.3 
Alprazolam 10.8 
Warfarin 9.2 
Hydrocortisone 6.7 
Promethazine 4.2 
Isosorbide 4.2 
Risperidone 3.3 
Digoxin 2.5 
Metoprolol 2.5 
Triamterene 2.5 
Ranitidine 1.7 
Fentanyl 1.7 
Olanzapine 1.7 
Carbamazepine 1.7 
Chlorpheniramine 0.8 
Atenolol 0.8 
Prednisolone 0.8 
Clozapine 0.8 
Nortriptyline 0.8 
Loperamide 0.8 
Oxcarbazepine 0.8 
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Table 5 a) Gender 
 All Female Male  
% of all patients 100.0 58.3 41.7  
Gender (%) Female 58.3 100.0 0.0  
Male 41.7 0.0 100.0 p <0.001 
Age Mean 79.6 81.0 77.7  
SD 13.1 13.5 12.3 p= 0.003 
Patients on AChE-I on admission (%) 6.7 5.3 8.3 p= 0.223 
Patients on DAPs on admission: (%) 60.8 58.1 64.6 p= 0.147 
ACB Score on admission  Range 0 - 10 0 – 8 0 – 10  
                                           Mean 1.3 1.3 1.4  
                                           SD 1.6 1.6 1.6 p= 0.558 
Patients on DAPs on discharge (%) 57.7 55.6 60.3 p= 0.319 
ACB score on discharge    Range 0 - 10 0 – 8 0 – 10  
                                           Mean 1.3 1.3 1.3  
                                           SD 1.6 1.6 1.6 p= 0.603 
Patients on temporary DAPs (%) 21.9 18.1 26.6  
ACB score temp.DAPs     Range 0 - 6 0  - 3 0 – 6  
                                          Mean 0.4 0.3 0.5  
                                          SD 0.9 0.7 1.1 p= 0.004 
Patients who had ACB reduced (%) 21.1 21.3 21.0 p= 1.000 
Patients who had ACB increased (%) 19.7 19.4 19.7 p= 1.000 
Patients with no change in ACB (%) 59.2 59.4 59.4 p= 1.000 
DAP naïve started on DAPs (%) 22.8 20.9 24.7 p= 1.000 
ACB on admission vs discharge p= 0.569 0.760 0.512  
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Table 5b) Diagnoses 
  All Dementia  Delirium  Falls  New dementia 
% off all patients 100.0 27.0            34.8            60.3            4.9            
Gender (%) Female 58.3 60.8            56.5            60.1            59.3            
Male 41.7 39.2 p= 0.563 43.5 p= 0.563 39.9 p= 0.380 40.7 p= 1.000 
Age Mean 79.6 83.7            79.3            79.5            88.2            
SD 13.1 7.1 p <0.001 12.1 p= 0.606 14.0 p= 0.819 5.2 p <0.001 
Patients on AChE-I on admission (%) 6.7 17.6 p <0.001 5.2 p= 0.396 5.7 p= 0.329 3.7 p= 1.000 
Patients on DAPs on admission: (%) 60.8 66.9 p= 0.096 64.4 p= 0.274 57.1 p= 0.026 63.0 p= 0.826 
ACB Score on admission  Range 0 - 10 0 – 7            0 – 7            0 – 10            0 - 6            
                                           Mean 1.3 1.5            1.5            1.3            1.5            
                                           SD 1.6 1.7 p= 0.144 1.6 p= 0.318 1.6 p= 0.134 1.8 p= 0.598 
Patients on DAPs on discharge (%) 57.7 58.1 p= 0.993 59.7 p= 0.603 56.8 p= 0.643 59.3 p= 1.000 
ACB score on discharge    Range 0 - 10 0 – 7            0 – 7            0 – 10            0 - 8            
                                           Mean 1.3 1.4            1.4            1.3            1.3            
                                          SD 1.6 1.8 p= 0.452 1.7 p= 0.277 1.6 p= 0.346 1.8 p= 0.959 
Patients on temporary DAPs (%) 21.9 17.6            23.6            20.8            11.1            
ACB score temp.DAPs     Range 0 - 6 0 – 4            0 – 6            0 – 5            0 - 5            
                                          Mean 0.4 0.3            0.4            0.3            0.3            
                                          SD 0.9 0.7 p= 0.072 1.0 p= 0.186 0.7 p= 0.137 1.0 p= 0.433 
Patients who had ACB reduced (%) 21.1 27.0 p= 0.053 23.6 p= 0.406 17.5 p= 0.015 25.9 p= 0.506 
Patients who had ACB increased (%) 19.7 18.9 p= 0.882 23.6 p= 0.118 17.8 p= 0.218 18.5 p= 1.000 
Patients with no change in ACB (%) 59.2 54.1 p= 0.164 52.9 p= 0.041 64.7 p= 0.002 55.6 p= 0.684 
DAP naïve started on DAPs (%) 22.8 28.6 p= 0.922 26.5 p= 0.887 20.4 p= 1.000 20.0 p= 1.000 
ACB on admission vs discharge p= 0.569 0.320            0.760            0.995            0.661            
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Table 5c) Patients on cholinesterase inhibitors (AChE-I) 
 All AChE-I on admission 
% of all patients 100.0 6.7  
Gender (%) Female 57.1 48.6  
Male 42.9 51.4 p= 0.290 
Age Mean 84.4 83.4  
SD 9.0 6.0 p= 0.001 
Patients on AChE-I on admission (%) 6.7 100.0  
Patients on DAPs on admission: (%) 60.8 54.1 p= 0.483 
ACB Score on admission  Range 0 - 10 0 – 6  
                                           Mean 1.3 1.3  
                                           SD 1.6 1.6 p= 0.933 
Patients on DAPs on discharge (%) 57.7 54.1 p= 0.766 
ACB score on discharge    Range 0 - 10 0 – 6  
                                           Mean 1.3 1.2  
                                           SD 1.6 1.6 p= 0.809 
Patients on temporary DAPs (%) 21.9 13.5  
ACB score temp.DAPs     Range 0 - 6 0 – 1  
                                          Mean 0.4 0.1  
                                          SD 0.9 0.3 p<0.001 
Patients who had ACB reduced (%) 21.1 13.5 p= 0.334 
Patients who had ACB increased (%) 19.7 13.5 p= 0.446 
Patients with no change in ACB (%) 59.2 73.0 p= 0.111 
DAP naïve started on DAPs (%) 22.8 23.5 p= 0.906 
ACB on admission vs discharge p= 0.569 0.755  
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Table 5d) Other subgroups   
  All Died during admission Short stay (3 days 
max) 
Unable to return home 30 day readmission 
% of all patients 100.0 7.7            22.6            18.9 100.0 7.7            
Gender (%)  Female 57.1            59.7            63.5            57.1            59.7 
  Male 
42.9 p= 0.965 40.3 p= 0.800 36.5 p= 0.228 42.9 p= 0.965 40.3 
Age  Mean 84.4            78.2            82.0            84.4            78.2 
  SD 
9.0 p= 0.001 13.4 p= 0.194 9.0 p <0.001 9.0 p= 0.001 13.4 
Patients on AChE-I on admission (%) 6.7 2.4 p= 0.394 7.3 p= 0.954 2.9 6.7 2.4 p= 0.394 
Patients on DAPs on admission: (%) 60.8 73.8 p= 0.104 57.3 p=0.410 61.5 60.8 73.8 p= 0.104 
ACB Score on admission  Range 0 – 10 0 – 5            0 – 10            0 - 6 0 – 10 0 – 5            
                                           Mean 1.3 1.6            1.3  1.3 1.3 1.6            
                                           SD 1.6 1.5 p= 0.309 1.8 p= 0.728 1.4 1.6 1.5 p= 0.309 
Patients on DAPs on discharge (%) 57.7 59.5 p= 0.916 48.4 p=0.022 66.3 57.7 59.5 p= 0.916 
ACB score on discharge    Range 0 – 10 0 – 7            0 – 10            0 - 8 0 – 10 0 – 7            
                                           Mean 1.3 1.3            1.1  1.6 1.3 1.3            
                                           SD 1.6 1.6 p= 0.898 1.7 p= 0.074 1.8 1.6 1.6 p= 0.898 
Patients on temporary DAPs (%) 21.9 38.1            18.5 p= 0.373 34.6 21.9 38.1            
ACB score temp.DAPs     Range 0 - 6 0 – 5            0 – 3  0 - 6 0 - 6 0 – 5            
                                          Mean 0.4 0.8            0.3            0.7 0.4 0.8            
                                          SD 0.9 1.4 p= 0.030 0.6 p= 0.056 1.2 0.9 1.4 p= 0.030 
Patients who had ACB reduced (%) 21.1 35.7 p= 0.027 21.0 p= 1.000 13.5 21.1 35.7 p= 0.027 
Patients who had ACB increased (%) 19.7 23.8 p= 0.594 8.9 p= 0.001 32.7 19.7 23.8 p= 0.594 
Patients with no change in ACB (%) 59.2 40.5 p= 0.015 70.2 p= 0.007 53.8 59.2 40.5 p= 0.015 
DAP naïve started on DAPs (%) 22.8 27.3 p= 0.922 15.1 p= 0.358 32.5 22.8 27.3 p= 0.922 
ACB on admission vs discharge p= 0.569 0.382            0.018  0.016 0.569 0.382            
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Table 6: Medications with anticholinergic properties used in patients on procholinergic drugs 
on admission 
Medication % 
  
Furosemide 16.1 
Alprazolam 9.7 
Quetiapine 9.7 
Isosorbide 6.5 
Risperidone 6.5 
Trazodone 6.5 
Olanzapine 6.5 
Ranitidine 3.2 
Quinidine 3.2 
Warfarin 3.2 
Codeine 3.2 
Fentanyl 3.2 
Morphine 3.2 
Aripiprazole 3.2 
Venlafaxine 3.2 
Amitriptyline 3.2 
Clozapine 3.2 
Nortriptyline 3.2 
Oxybutynin 3.2 
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Figure 1: Adapted Anticholinergic Burden Scale
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Figure 2: Medications with anticholinergic properties in all patients on admission and 
discharge
  
Page 29 of 31 Journal of Clinical Pharmacy and Therapeutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Figure 3: Medications with anticholinergic properties in all patients on admission and 
discharge, weighted by their individual anticholinergic burden
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Figure 4: Distribution of anticholinergic burden on admission and discharge by diagnosis
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